ORPN vs. BLPH, EVFM, ADTX, SBFM, SXTC, EVLO, SPRC, ATHX, APVO, and AMPE
Should you be buying Bioblast Pharma stock or one of its competitors? The main competitors of Bioblast Pharma include Bellerophon Therapeutics (BLPH), Evofem Biosciences (EVFM), Aditxt (ADTX), Sunshine Biopharma (SBFM), China SXT Pharmaceuticals (SXTC), Evelo Biosciences (EVLO), SciSparc (SPRC), Athersys (ATHX), Aptevo Therapeutics (APVO), and Ampio Pharmaceuticals (AMPE). These companies are all part of the "medical" sector.
Bioblast Pharma (NASDAQ:ORPN) and Bellerophon Therapeutics (NASDAQ:BLPH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.
Bellerophon Therapeutics received 107 more outperform votes than Bioblast Pharma when rated by MarketBeat users. However, 78.23% of users gave Bioblast Pharma an outperform vote while only 60.53% of users gave Bellerophon Therapeutics an outperform vote.
Bellerophon Therapeutics has a consensus target price of $2.00, indicating a potential upside of 3,100.00%. Given Bellerophon Therapeutics' higher possible upside, analysts plainly believe Bellerophon Therapeutics is more favorable than Bioblast Pharma.
Bioblast Pharma's return on equity of 0.00% beat Bellerophon Therapeutics' return on equity.
4.5% of Bioblast Pharma shares are held by institutional investors. Comparatively, 10.6% of Bellerophon Therapeutics shares are held by institutional investors. 5.2% of Bellerophon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Bioblast Pharma has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500. Comparatively, Bellerophon Therapeutics has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500.
In the previous week, Bellerophon Therapeutics had 1 more articles in the media than Bioblast Pharma. MarketBeat recorded 1 mentions for Bellerophon Therapeutics and 0 mentions for Bioblast Pharma. Bioblast Pharma's average media sentiment score of 0.00 equaled Bellerophon Therapeutics'average media sentiment score.
Summary
Bioblast Pharma and Bellerophon Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.
Get Bioblast Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ORPN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ORPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bioblast Pharma Competitors List
Related Companies and Tools
